Sharon Klahre | executive |
Michael Metzger | executive |
Neil Gallagher | executive |
Steven Closter | executive |
Keith Goldan | executive |
Peter Lawson | analyst |
Anupam Rama | analyst |
Bradley Canino | analyst |
Philip Nadeau | analyst |
Anjali Ganguli | executive |
Michael Schmidt | analyst |
Michael Meyers | executive |
Yigal Nochomovitz | analyst |
Kalpit Patel | analyst |
Justin Zelin | analyst |
Chris Shibutani | analyst |
George Farmer | analyst |
Good day, everyone, and welcome to the Syndax First Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I'd like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's First Quarter 2024 Financial and Operating Results.